Systems and methods of improving an inflammatory disorder

• US 10,201,706 B2
• Filed: 12/19/2016
• Issued: 02/12/2019
• Est. Priority Date: 05/15/2015
• Status: Active Grant

• Current Assignee: Ohio State Innovation Foundation (Ohio State University)
• Original Assignee: Ohio State Innovation Foundation (Ohio State University)
• Inventors: Schwab, Jan, Popovich, Phillip, Rezai, Ali R.
• Primary Examiner(s): Holmes, Rex R
• Application Number:
  US15/382,950
• Publication Number:
  US 20170120046A1
• Time in Patent Office: 785 Days
• CPC Class Codes: A61M 5/14276 specially adapted for implantation
• CPC Class Codes: A61M 5/1723 using feedback of body parameters, e.g. blood-sugar, pressure measurement of body parameters A61B5/00
• CPC Class Codes: A61N 1/36014 External stimulators, e.g. with patch electrodes external pacemakers A61N1/3625
• CPC Class Codes: A61N 1/3606 adapted for a particular treatment
• CPC Class Codes: A61N 2005/0659 infrared
• CPC Class Codes: A61N 2007/0026 Stimulation of nerve tissue
• CPC Class Codes: A61N 5/022 Apparatus adapted for a specific treatment

Abstract

Methods for improving an inflammatory disorder in a subject are provided. Methods include positioning a therapy delivery device on a neural target site that contributes to immune activity of the subject. The therapy delivery device is activated to deliver a therapy signal to the neural target site to improve the subject'"'"'s inflammatory disorder.

Claims

1. A method of improving an inflammatory disorder in a subject suffering therefrom comprising:

positioning a therapy delivery device in communication with a neural target site, comprising at least a part of the enteric nervous system, that contributes to immune activity of the subject;

sensing, by at least one of an electrical sensor and a biological sensor, at least one physiological parameter of immune activity of the enteric nervous system that is indicative of an inflammatory disorder of the subject, wherein the at least one of the electrical sensor and biological sensor is disposed at an enteric plexus or ganglion;

delivering, by the therapy delivery device, a therapy signal to the neural target site, wherein delivery parameters of the therapy signal are selected based on the sensed at least one physiological parameter to modulate an immune response of the subject to treat the subject'"'"'s inflammatory disorder.

2. The method of claim 1, wherein inflammatory disorder comprises atherosclerosis.

3. The method of claim 1, wherein the inflammatory disorder comprises myocarditis, nephritis, prostatitis, sinusitis, or organ-based inflammation.

4. The method of claim 1, wherein the inflammatory disorder comprises joint inflammation.

5. The method of claim 1, wherein the inflammatory disorder comprises non-allergic asthma.

6. The method of claim 1, wherein the inflammatory disorder comprises an inflammatory bowel disease.

7. The method of claim 6, wherein the inflammatory bowel disease is Crohn'"'"'s disease or ulcerative colitis.

8. The method of claim 1, wherein the inflammatory disorder comprises acute respiratory distress syndrome (ARDS) or chronic respiratory distress syndrome (CRDS).

9. The method of claim 1, wherein the inflammatory disorder comprises acute lung injury.

10. The method of claim 1, wherein the inflammatory disorder comprises neurogenic lung edema.

11. The method of claim 1, wherein the subject is livestock.

12. The method of claim 1, wherein the subject is a human.

13. The method of claim 1, wherein the neural target site comprises a thoracic or lumbar segment of the spinal cord.

14. The method of claim 13, wherein the thoracic segment is a T5-T-9 thoracic segment.

15. The method of claim 1, wherein the neural target site comprises a thoracic or lumbar spinal nerve root.

16. The method of claim 1, wherein the neural target site comprises a neural target site selected from the group consisting of a celiac ganglion, an aorticorenal ganglion, a pulmonary plexus, a superior mesenteric ganglion, an inferior mesenteric ganglion, a superior hypogastric ganglion, a lumbar plexus, a sympathetic chain ganglion, a greater splanchnic nerve, a lesser splanchnic nerve, a least splanchnic nerve, and a dorsal root ganglion.

17. The method of claim 1, wherein the neural target site comprises a dermatome specific to thoracic or lumbar levels of a spinal cord of the subject.

18. The method of claim 1, wherein the neural target site comprises a nerve that innervates or receives input from the spleen, bone marrow, the thymus, a lymph node, immune cells, the kidney, the adrenal gland or the lungs.

19. A method of improving an inflammatory disorder in a subject comprising:

sensing, by at least one of an electrical sensor and biological sensor, the level of at least one physiological parameter that is indicative of immune activity of the enteric nervous system of the subject, wherein the at least one of the electrical sensor and biological sensor is disposed at an enteric plexus or ganglion;

predicting dysfunction of the subject'"'"'s immune system by comparing the determined level of the at least one physiological parameter with a control value and determining, based on the comparison, that the level of the at least one physiological parameter is indicative of an inflammatory disorder of the subject;

placing a therapy delivery device into communication with a neural target site, comprising at least a part of the enteric nervous system, that contributes to immune activity of the subject; and

delivering, by the therapy delivery device, a therapy signal to the neural target site, wherein delivery parameters of the therapy signal are selected based on the sensed at least one physiological parameter to modulate an immune response of the subject to treat the subject'"'"'s inflammatory disorder.